Zydus Cadila completes phase 2 clinical trial in COVID-19 patients with biological therapy PegiHep

In a regulatory filing, Zydus Cadila said "it has successfully completed a phase 2 clinical trial in COVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHep'... Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India".

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3pw774m
via IFTTT